Clinical trial
Safety of 32P BioSilicon in Patients With Hepatocellular Carcinoma
NCT00247260 · pSiVida Limited, Industry · Unknown status
Key facts
| NCT number | NCT00247260 |
|---|---|
| Title | Safety of 32P BioSilicon in Patients With Hepatocellular Carcinoma |
| Official title | A Study of the Safety Profile of Three Escalating Radioactivity Levels of 32P BioSilicon Delivered With the SIMPL Needle as Intratumoural Implantations in Patients With Unresectable Hepatocellular Carcinoma |
| Lead sponsor | pSiVida Limited, Industry |
| Collaborators | pSiOncology Private Limited |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Device |
| Interventions | 32P BioSilicon |
| Enrollment | 50 |
| Start date | Oct 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | Nov 1, 2005 |
| Last update posted | Mar 15, 2007 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: